Relay Therapeutics, Inc.

NASDAQ:RLAY

Biotechnology

Healthcare
$15.91 +2.63%

+$0.41 today

Market cap
$3.52B
Beta
1.75
P/E (TTM)
-10.5
EPS (TTM)
-$1.52
52W Low $3.03High $17.47

Volume 1.88M

Average 3.70M

Income Statement

Follow revenue through to earnings.

Revenue

$15.36M

FY 2025 · Annual

+53.4% YoY

Operating Income

-$302.74M

FY 2025 · Annual

Net Income

-$276.48M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.03M1.38M25.55M10.01M15.36M
Cost of Revenue169.39M243.01M326.39M315.44M3.56M
Gross Profit(166.36M)(241.62M)(300.84M)(305.43M)11.8M
Gross Margin-5492.2%-17496.3%-1177.6%-3052.2%76.8%
Research & Development295.65M246.36M330.02M319.09M261.38M
Selling, General & Admin59.75M69.33M78.58M80.24M56.71M
Operating Expenses198.34M57.65M72.16M67.03M314.54M
Depreciation & Amortization3.93M4.13M5.27M5.46M3.56M
EBITDA(223.08M)(306.82M)(374.15M)(380.21M)(272.92M)
EBITDA Margin-7364.9%-22217.4%-1464.6%-3799.4%-1777.4%
Operating Income(364.7M)(299.28M)(373M)(372.47M)(302.74M)
Operating Margin-12040.2%-21670.9%-1460.1%-3722.1%-1971.6%
Interest Income830K8.79M31.05M34.75M27.04M
Interest Expense00000
Other Income / Expenses826K8.77M31.03M34.76M26.26M
Income Before Tax(363.87M)(290.51M)(341.97M)(337.71M)(276.48M)
Pre-Tax Margin-12012.9%-21036.1%-1338.7%-3374.7%-1800.6%
Income Tax Expense00000
Net Income(363.87M)(290.51M)(341.97M)(337.71M)(276.48M)
Net Margin-12012.9%-21036.1%-1338.7%-3374.7%-1800.6%
EPS (Basic)(3.82)(2.59)(2.79)(2.36)(1.61)
EPS (Diluted)(3.82)(2.59)(2.79)(2.36)(1.61)
Weighted Avg Shares95.14M112.23M122.58M142.87M171.59M
Weighted Avg Shares (Diluted)95.14M112.23M122.58M142.87M171.59M

RLAY Earnings Waterfall · TTM

NASDAQ:RLAY · Revenue to Net Income

Key Ratios

EPS$-1.57
Gross Margin68.7%
Net Margin-6785.9%
P/E Ratio-6.8
P/S Ratio2911.9

Analysis

$10.3M of revenue converted into -$286.0M of net income for the selected period. Gross margin is 68.7% and net margin is -6785.9%, showing how much revenue survives after costs and taxes. EPS is $-1.57, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 4, 2026
10-QQuarterly reportNov 4, 2026
4Statement of changes in beneficial ownershipOct 30, 2026
4Statement of changes in beneficial ownershipOct 30, 2026
4Statement of changes in beneficial ownershipOct 30, 2026

How much revenue does RLAY generate?

Relay Therapeutics, Inc. (RLAY) reported $15.36M of revenue in fiscal 2025.

Is RLAY profitable?

Relay Therapeutics, Inc. (RLAY) reported -$276.48M of net income, with a net margin of -1800.6%.